Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2012

ABL and MicroTest Separately Announce Contract Manufacturing Deals

  • Advanced BioScience Laboratories (ABL) and MicroTest separately reported on the signing of new contract manufacturing agreements. ABL will carry out scale-up and cGMP production of Trophogen’s recombinant human follicle stimulating hormone (rhFSH) analog for Phase I/II clinical studies projected to start in 2014. The rhFSH analog is Trophogen’s lead compound in its superagonist hormone technology platform licensed from the NIH.  

    Microtest will manufacture and provide supporting pharmaceutical testing services for ImmusanT’s Nexvax2® immunotherapeutic vaccine for a forthcoming trial as a treatment for celiac disease. The candidate has already undergone a Phase I clinical study. ImmusanT recently raised $20 million in financing to progress development of Nexvax2.

    Part of the Institut Merieux, ABL is a CRO and manufacturing firm with specialized expertise in therapeutics, vaccines, and other biological products. Its capabilities span basic research, product design, process and assay development, through to preclinical in vivo models, and Phase I/II cGMP biological manufacturing.

    Microtest provides a full range of testing services, contract manufacturing, and fill/finish services for the medical device, pharmaceutical, and biotech industries.   



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »